Dehghani Seyed Mohsen, Taghavi Seyed Ali Reza, Eshraghian Ahad, Gholami Siavash, Imanieh Mohammad Hadi, Bordbar Mohammad Reza, Malek-Hosseini Seyed Ali
Organ Transplantation Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
J Gastroenterol. 2007 Sep;42(9):769-74. doi: 10.1007/s00535-007-2092-2. Epub 2007 Sep 25.
Hyperlipidemia is a metabolic complication after liver transplantation (LT). The aim of this study was to investigate the prevalence and risk factors for developing hyperlipidemia in patients who underwent LT in the Shiraz Organ Transplantation Center.
Our patients were 170 liver recipients who underwent LT from 1994 to 2006 in the Organ Transplantation Center of the Shiraz University of Medical Sciences. To perform this study we administered questionnaires, including information about age, sex, body mass index (BMI), underlying liver disease, graft type, immunosuppressive medications, and serum levels of triglycerides and cholesterol, before and 6 months after LT. Serum triglyceride and cholesterol levels were considered elevated if they were >150 mg/dl and >250 mg/dl, respectively. Data were analyzed with SPSS software.
There were 108 male and 62 female patients, with a mean age of 31.4 +/- 13.3 years, and the mean duration of follow-up was 25.9 +/- 23.5 months. The average pretransplant serum triglyceride and cholesterol (mean of individual means) levels were 104.6 +/- 73.2 and 109.5 +/- 51.5 mg/dl, respectively, and the average posttransplant levels were 230.1 +/- 131 and 185 +/- 77 mg/dl, respectively. Six months after LT, 119 (70%) and 26 (15.3%) patients developed hypertriglyceridemia and hypercholesterolemia, respectively. Age, sex, BMI, and underlying liver disease were not predictors of hypertriglyceridemia or hypercholesterolemia (P > 0.05). Posttransplant hypertriglyceridemia was significantly more common in patients receiving tacrolimus than in those receiving cyclosporine (P = 0.040), but posttransplant hypercholesterolemia had no significant correlation with type of immune suppression (P > 0.05).
Hyperlipidemia was common after LT, and hypertriglyceridemia was more common than hypercholesterolemia. Among all risk factors, tacrolimus therapy was correlated with development of hypertriglyceridemia after LT.
高脂血症是肝移植（LT）后的一种代谢并发症。本研究旨在调查设拉子器官移植中心接受肝移植患者中高脂血症的患病率及危险因素。
我们的研究对象为1994年至2006年在设拉子医科大学器官移植中心接受肝移植的170例肝移植受者。为开展本研究，我们在肝移植前及移植后6个月发放问卷，内容包括年龄、性别、体重指数（BMI）、潜在肝脏疾病、移植物类型、免疫抑制药物以及甘油三酯和胆固醇的血清水平。若血清甘油三酯水平>150mg/dl且胆固醇水平>250mg/dl，则认为其升高。数据采用SPSS软件进行分析。
共有108例男性和62例女性患者，平均年龄为31.4±13.3岁，平均随访时间为25.9±23.5个月。移植前血清甘油三酯和胆固醇（个体均值的平均值）水平分别为104.6±73.2和109.5±51.5mg/dl，移植后平均水平分别为230.1±131和185±77mg/dl。肝移植后6个月，分别有119例（70%）和26例（15.3%）患者发生高甘油三酯血症和高胆固醇血症。年龄、性别、BMI和潜在肝脏疾病不是高甘油三酯血症或高胆固醇血症的预测因素（P>0.05）。移植后接受他克莫司治疗的患者高甘油三酯血症明显比接受环孢素治疗的患者更常见（P = 0.040），但移植后高胆固醇血症与免疫抑制类型无显著相关性（P>0.05）。
肝移植后高脂血症常见，高甘油三酯血症比高胆固醇血症更常见。在所有危险因素中，他克莫司治疗与肝移植后高甘油三酯血症的发生相关。
